The recent surge in capital into specialized pharmaceutical companies, particularly those focusing on experimental therapies and difficult drug development programs, has fueled what some are calling "High Roller Pharma." While the possibility for revolutionary treatments and impressive returns is certain, the associated risks are also significant.